TENAX THERAPEUTICS, INC. — Director's Dealing 2021

Jan 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TENAX THERAPEUTICS, INC. (TENX)
CIK: 0000034956
Period of Report: 2021-01-15

Reporting Person: Rich Stuart (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-15	Common Stock	A	662517	—	Acquired	662517	Direct
2021-01-15	Series B Preferred Stock	A	3581	—	Acquired	3581	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-15	Stock Option (right to buy)	$1.78	A	250000	Acquired	2031-01-15	Common Stock (250000)	Direct

Footnotes

F1: The reporting person acquired the securities in connection with the merger of PHPrecisionMed Inc. with and into a wholly owned subsidiary of Tenax Therapeutics, Inc. (the "Transaction").

F2: The option becomes exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA.